ReviewExpert review of clinical immunology2019
Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases.
Review in Expert review of clinical immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis.Gastroenterology · 2024Guideline
- Risk of Urinary Bladder Cancer in Patients With Inflammatory Bowel Diseases: A Meta-Analysis.Frontiers in surgery · 2021Pooled it
- Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19.Journal of Crohn's & colitis · 2020Guideline
- Successful transition to mirikizumab following hepatic abscess during adalimumab therapy in a patient with ulcerative colitis.Clinical journal of gastroenterology · 2026Article
- Immunoregulatory protein-hybrid extracellular vesicles via self-loadable backbone cyclization for oral inflammatory bowel disease therapy.Bioactive materials · 2026Article
- Immunomodulators, Biologics, and 5-ASA for Inflammatory Bowel Disease and Major Adverse Cardiovascular Events in Older Adults.JAMA network open · 2026Article
- Comparative Safety of Janus Kinase Inhibitors vs Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026Article
- A Comparison of Biological Therapies vs Traditional Immunosuppressant in the Management of Inflammatory Bowel Diseases: A Narrative Review.Journal of community hospital internal medicine perspectives · 2026Review
- Infliximab asFrontiers in gastroenterology (Lausanne, Switzerland) · 2026Article
- Article
- Unveiling the differences: infection disorders associated with tumor necrosis factor α inhibitors in pediatric patients-a pharmacovigilance study (2004-2023).European journal of pediatrics · 2025Article
- Unleashing the potential of extracellular vesicles for ulcerative colitis and Crohn's disease therapy.Bioactive materials · 2025Review
- Advancements in dual biologic therapy for inflammatory bowel diseases: efficacy, safety, and future directions.Therapeutic advances in gastroenterology · 2025Review
- Panduratin A mitigates inflammation and oxidative stress in DSS-induced colitis mice model.Future science OA · 2024Article
- Medication Burden Before and After Prescription of Biologics in Patients with Inflammatory Bowel Disease.Journal of clinical medicine · 2024Article
- Impact of Treatment Response on Risk of Serious Infections in Patients With Crohn's Disease: Secondary Analysis of the PYRAMID Registry.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024Article
- Article
- Comparative risk of serious infections and tuberculosis in Korean patients with inflammatory bowel disease treated with non-anti-TNF biologics or anti-TNF-α agents: a nationwide population-based cohort study.Therapeutic advances in gastroenterology · 2024Article
- Comparative Persistence of Non-tumor Necrosis Factor (TNF) vs. TNF Antagonists for Post-operative Prophylaxis in Crohn's Disease (CD).Digestive diseases and sciences · 2024Article
- An Engineered Probiotic Produces a Type III Interferon IFNL1 and Reduces Inflammations inACS biomaterials science & engineering · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.